Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
about
Fingolimod for relapsing-remitting multiple sclerosisSodium channel blockers for neuroprotection in multiple sclerosisSodium channel blockers for neuroprotection in multiple sclerosisOptimizing treatment success in multiple sclerosisPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisSystematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosisNeuroprotection in a novel mouse model of multiple sclerosisThe EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.Introduction: cognitive dysfunction in multiple sclerosisSound Lateralization Test Distinguishes Unimpaired MS Patients from Healthy Controls.Quantitative assessment of finger motor impairment in multiple sclerosis.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Outcome Measures in Clinical Trials for Multiple Sclerosis.Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosisSocial participation in patients with multiple sclerosis: correlations between disability and economic burden.Targeting Cognitive Impairment in Multiple Sclerosis-The Road toward an Imaging-based BiomarkerPatient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29.Activities of daily living and lesion position among multiple sclerosis patients by Bayes network.The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool.Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot studyProtection of Tregs, suppression of Th1 and Th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline.Cinnamon ameliorates experimental allergic encephalomyelitis in mice via regulatory T cells: implications for multiple sclerosis therapy.Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysisVision in a phase 3 trial of natalizumab for multiple sclerosis: relation to disability and quality of lifeGradient echo magnetic resonance imaging correlates with clinical measures and allows visualization of veins within multiple sclerosis lesionsA Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.Disability and Fatigue Can Be Objectively Measured in Multiple SclerosisProspects of Cinnamon in Multiple Sclerosis.Future MS care: a consensus statement of the MS in the 21st Century Steering Group.Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.Usability and Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using Depth-Sensing Computer Vision.Brain reserve against physical disability progression over 5 years in multiple sclerosis.Glyceryl Tribenzoate: A Flavoring Ingredient, Inhibits the Adoptive Transfer of Experimental Allergic Encephalomyelitis via TGF-β: Implications for Multiple Sclerosis Therapy.Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.Treatment trials in progressive MS--current challenges and future directions.Neuroprotection in multiple sclerosis: a therapeutic approach.Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.
P2860
Q24185882-A999F0E8-7473-44DC-AED3-A96F0BD5F429Q24186448-BDCC8F50-84D6-4ED5-AFA6-9BC8BAE442E7Q24200461-8579674C-BFC7-4E7D-A3BC-DAF3B62E7B6DQ26771968-C55E228F-2EF1-4989-9AD7-813CFC77CA0DQ27000269-821AB1AD-167D-4460-816C-7D4F5C20D01FQ27004079-AFAF78E4-FFDB-45F9-BE95-F032A647CF35Q27302918-9FFD6C6B-D57B-4BB6-8894-BD268DB58EBBQ30277106-B878A922-0596-4FCB-B693-E1691ED707EAQ30415225-79481492-7F1F-4E24-B6FB-EC38017D8D6BQ30432891-1E99CD69-DBC0-41CC-BAEE-342F0FE0A728Q30453819-A1348C7D-F5B9-446D-88E2-ABF6194E886CQ30458930-66406150-05A4-4A02-9E02-DC01654317FFQ31160866-9A82D771-C945-4F1F-B706-E2D459F662E8Q31162456-0DD7BE9F-922E-4CD6-AF52-7C3B810E9161Q33605310-F3EC9D83-FC7D-4B9E-9CA8-A04BD0CC7EF7Q33605353-3EEA5045-16C6-4895-BC68-074B91EA5B97Q33605465-17680990-1A34-4271-B033-610A8EBA9F89Q33729957-CF5B4D7D-2B92-47CE-BADA-621E7D276CEEQ33855765-C9EFFD8E-ECBC-4ACA-A415-A69D3F01A34AQ33887859-99FEDB29-F4D4-4871-87D0-003CFEE97D42Q33937065-03DB2E4B-9B7E-4FD4-A1EB-4F8F30F34F9AQ34406601-00741A07-3C45-4899-9370-739B0968C53BQ34481282-FD13C2B1-F107-4040-8793-D5C96969F777Q34532426-EC8D9AD2-D2F5-4A7D-B70D-B7014D0E4ECCQ34876505-D341FFAD-8EFD-4D05-B663-BC5670BDF73BQ35098877-5EBA595F-B900-4564-AA93-8101395BB6CAQ35111163-DF2F033B-5F03-496F-BE6A-D79B925754B8Q35198492-5D91C875-486C-4404-AAF8-EA797E0AD039Q35747637-AFB33DF3-051F-4DA5-9B9C-C6115CD9F2B1Q35919582-A3A109AE-D5E9-4BDE-9282-FD903B4D2DFBQ36057286-247A02DE-7C83-4BD0-81CE-67597BF0537CQ36592674-FB068325-A77A-44AE-ACC4-A507CB3F20B1Q36613404-FD8CD54E-C0E1-4193-9C99-73132CBDEBDAQ36701978-8B4FF9AC-F8FF-4F25-A4F3-53602B406E5BQ36951608-2BFDE122-0858-4C5D-A859-BF256CAC6904Q37730541-0C2D7169-2850-42D4-9245-62A4CEB5F422Q38022219-050B976F-CF5C-4078-A9F6-668486C8EBBEQ38125123-525B8432-8B09-41D4-A120-A8087EF06ED0Q38129748-42A051A1-E5B3-44A5-8ED6-1217F89A3529Q38140702-65333394-D459-4C23-809C-54CF610CECFE
P2860
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Disability outcome measures in ...... nt status and future prospects
@ast
Disability outcome measures in ...... nt status and future prospects
@en
Disability outcome measures in ...... nt status and future prospects
@nl
type
label
Disability outcome measures in ...... nt status and future prospects
@ast
Disability outcome measures in ...... nt status and future prospects
@en
Disability outcome measures in ...... nt status and future prospects
@nl
prefLabel
Disability outcome measures in ...... nt status and future prospects
@ast
Disability outcome measures in ...... nt status and future prospects
@en
Disability outcome measures in ...... nt status and future prospects
@nl
P2093
P1433
P1476
Disability outcome measures in ...... nt status and future prospects
@en
P2093
Chris H Polman
Jeffrey A Cohen
Jerry S Wolinsky
Stephen C Reingold
P304
P356
10.1016/S1474-4422(12)70059-5
P407
P577
2012-05-01T00:00:00Z